EP1226172A1 - Composes, anticorps et methodes destines au traitement, a la prevention ou au diagnostic de la metastase des tumeurs - Google Patents

Composes, anticorps et methodes destines au traitement, a la prevention ou au diagnostic de la metastase des tumeurs

Info

Publication number
EP1226172A1
EP1226172A1 EP99960062A EP99960062A EP1226172A1 EP 1226172 A1 EP1226172 A1 EP 1226172A1 EP 99960062 A EP99960062 A EP 99960062A EP 99960062 A EP99960062 A EP 99960062A EP 1226172 A1 EP1226172 A1 EP 1226172A1
Authority
EP
European Patent Office
Prior art keywords
wnt
cancer
metastasis
cells
synthesised peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99960062A
Other languages
German (de)
English (en)
Inventor
Marzieh JÖNSSON
Tommy Experim. Pathology ANDERSSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forskarpatent I SYD AB
Original Assignee
Forskarpatent I SYD AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forskarpatent I SYD AB filed Critical Forskarpatent I SYD AB
Publication of EP1226172A1 publication Critical patent/EP1226172A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to a novel synthesised peptide- analogue, including the functional domain of the nt-5a protein, a composition comprising the peptide-analogue.
  • the invention is also related to uses of the compound for the manufacture of a medicament or producing of a diagnostic agent in the treatment of metastasis or the diagnosing of metastasis. Furthermore, the invention relates to method of anti- metastasis treatment and diagnoses.
  • the metastasis process involves the entry of cells from the primary tumours into the blood and lymphatic circulation and their exit at metastatic sites.
  • Cells from different primary tumours do metastasise into different distal organs, for example breast tumours mainly metastasise into the bone marrow and the lungs.
  • breast tumours mainly metastasise into the bone marrow and the lungs.
  • About 70% of patients with advanced cancers suffer from distal metastases and thereby increased mortality.
  • Organ-conserving approaches are of high priority considering psychological devastation for the patients, although organ-preserving methods will increase the risk for cancer metastasis.
  • a phenomenon referred to as multiple drug resistance i.e. resistance to a wide range of structurally unrelated anticancer drugs, has caused several problems in treatment of various cancers with chemotherapeutic approaches. Even a patient receiving cytotoxic anti -cancer treatment is exposed to developing drug-resistant populations, which will multiply and eventually enter the circulation and infiltrate other organs. Thus, an anti-metastasis approach that functions in a wide variety of situations and tumour types, where a risk for the development of metastases exist, is of crucial significance .
  • tumour cells are a tumorogenic phenotype, which is transformed into a non-tumorogenic phenotype.
  • compositions and methods for transfection of tumour cells under conditions such that tumour growth is suppressed are transfected with the nucleic acid comprising the Wnt-5a gene.
  • the problem with this solution is that the tumour cells have to be transfected to suppress the tumour growth.
  • the present invention solves the problem by the use of synthesised peptide-analogue including the functional domain of the Wnt-5a protein in the surpressing or blocking of metastasis cells.
  • the advantage of using synthesised peptide-analogue including the functional domain of the Wnt-5a protein in therapeutic treatments is that it makes it possible for instance to avoid the use of virus particles.
  • the Wnt gene family encodes secreted signalling proteins, which are conserved in many species and are involved in em- bryogenesis. The signalling proteins are also involved in the regulation of a wide variety of normal and pathological proc- esses.
  • MMTV mouse mammary tumour virus
  • the discovery of a locus, which was activated in response to insertion of mouse mammary tumour virus (MMTV) led to identification of a mouse proto-oncogene called int-1 (for MMTV integration site) .
  • the int-1 gene was later shown to be homologous to the Drosophila wingless (wg) gene, which is involved in embryonic segmentation and the combination of these two terms gave rise to the name 'WNT'.
  • wg Drosophila wingless
  • the signals derived from extracellular Wnt proteins are transmitted and sensed by neighbouring cells through an auto- crine or paracrine mechanism.
  • the diversity of function between different members of the Wnt family allows them to be divided into two distinct classes. These classes are designated as the Wnt-1 and the Wnt-5a class, which are described by Dale, T. C. Biochem. J. (1998) 329 : 209-223.
  • genes of the Wnt-1 class are capable of cell transformation and tumourigenesis .
  • the Wnt-1 and IVnt-3 genes of the Wnt-1 class can induce tumour growth in mouse mammary tissue when they are activated by insertion of mouse mammary tumour virus.
  • the Wnt -5a expression was found to induce adhesion of mammary epithelial cells to collagen, which is a dominant extracellular component associated with the periductal matrix in breast tissue. This induced ability to bind tightly onto the matrix was accompanied by phosphorylation and activation of discoidin domain 1 tyrosine kinase receptors, which was described by Vogel, W. FASEB. Supp. (1999) p. 77 - 82. In addition, cells expressing Wnt-5a protein proved to resist the inductive effect of hepatocyte growth factor (Gherardi, E. et al . Cancer Cells . (1991) 3:227-232) on cell motility, whereas Wnt-5a antisense cells invade the surrounding matrix extensively.
  • the treatment with the synthesised peptide-analogue which includes the functional domain of the Wnt-5a protein according to the present invention, will prevent the entry of disseminated cancer cells into blood or lymphatic circulation.
  • Various methods can be applied for supplying the compound (s) to the tumour cells under such conditions that cancer metastasis is blocked.
  • the present invention also contemplates the use of diagnostic methods for prediction of risk factor for the development of invasive carcinoma and recurrence. It has surprisingly been found that the Wnt-5a protein strengthens cell to matrix interaction. Therefore, it is predictable that a peptide-analogue comprising the functional domain of the Wnt-5a protein, can generate signals that force the disseminated cells to adhere effectively to the matrix. Accordingly, free movement of the cells and thereby ability to metastasise will be blocked.
  • the Wnt-5a protein sequence (published sequence accessible in several gene banks)
  • one embodiment of the present invention is a synthesised peptide-analogue, which includes the functional domain of the Wnt-5a protein. This domain is encoded from at least a part of the Wnt -5a gene for the treatment or the pre- vention of tumour metastasis.
  • Another embodiment of the present invention is a composition including a synthesised peptide-analogue.
  • Another embodiment of the present invention is an antibody derived from immunisation in mammals with the synthesised peptide-analogue or the composition.
  • the antibody is used as a diagnostic agent in diagnosing metastasis derived from all types of solid tumours such as breast cancer, prostatic can- cer, colon cancer or melanoma cancer.
  • Another embodiment of the present invention is the use of the synthesised peptide-analogue for the production of a medicament for the inhibiting of disseminated cells free movement and thereby blocking the metastasis .
  • Another embodiment of the present invention is a method of treatment or prevention of metastasis derived from all types of solid tumours such as breast cancer, prostatic cancer, colon cancer or melanoma cancer etc.
  • a further embodiment of the present invention is to provide a method for diagnosing cancer, comprising use of Wnt-5a antibody provided by invention.
  • invasive tumours can easily be detected when cancer disease is suspected.
  • This diagnostic step will provide guidance for radiation and chemo-therapeutic treatments.
  • Preferred embodiments and other aspects of the present invention are defined in the dependent claims.
  • the present invention thus provides a new composition com- prising the functional domain of tumour suppressor protein Wnt-5a, under conditions that prevent tumour metastasis.
  • the invention contemplates application of the Wnt-5a peptide with a variety of treatment methods .
  • the interval of rest periods can be extended to increase life quality of the patient with- out taking any risk for tumour cell dissemination and recurrence.
  • This method will eliminate the need for radiation for patients with negative lymph node metastasis and patient with positive lymph node will benefit from decreased radiation dose or intensity in their therapy.
  • the application can ra- tionally be combined with chemo-therapeutic regimens without recourse to other potentially confounding treatments.
  • expression of Wnt-5a is restricted to epithelial and stem cells, the Wnt-5a peptide will not interfere with the movement of other motile cells such as periphery blood cells.
  • the invention provides among others access to and insight in strengthening of cell to matrix adhesion by initiation of Wnt-5a signalling pathway in cells other than mammary epithelial as well.
  • Figure 1 Expression of Wnt-5a normalised the morphology of MCF-7 breast cancer cells.
  • A Morphology of MCF-7 untrans- fected parental cells.
  • B Morphology of MCF-7 control cells.
  • C Morphology of the MCF-7 cells expressing Wnt-5a protein.
  • Figure 2 The cell to collagen binding ability of various HB2 cell populations. The values represent the average number of cells attached to collagen during 1-hour incubation. The assay was performed in triplicate wells coated with various concentrations of collagen I as indicated.
  • Figure 3 Wnt-5a antisense cells invade the surrounding collagen matrix. The micrographs show: (A) The structures formed by control cells. (B) Structures formed by Wnt-5a-expressing cells that were primarily ball-like. (C) Structures generated by Wnt-5a antisense cells were mostly cyst-shaped. (D) To quantify the results, 100 morphogenetic structures were examined. Each of the structures were examined on triplicate plates and classified as cyst shaped, branching, or ball- like; the mean values of the number of structures in each class were then calculated and plotted in the illustrated diagram. Bar, 80 ⁇ m.
  • FIG. 4 Wnt-5a antisense cells show an increased capacity to invade matrix in response to the HGF stimulation.
  • the mi- crographs show: (A) Structures produced by control cells.
  • D The illustrated diagram was created by quantifying the morphogenetic structures as described in fig. 8. Bar, 80 ⁇ m.
  • FIG. 5 Example of Wnt-5a lost in invasive breast tumours.
  • the ductal carcinoma cells infilterating surrounding tissue have lost expression (single arrowhead) of Wnt-5a protein while the cells found in ductal in situ express this protein strongly (double arrowheads) .
  • the C-terminal end of the Wnt -5a gene was tagged with a HA (hemagglutinin) epitope and cloned into plasmid Bluescript KS+ (Shimizu, H. et al . Cell Growth Differ. (1997) 8 : 1349- 58) .
  • the Wnt-5a-HA cDNA was removed from pBluescript and sub- cloned into a retroviral vector, pLNCX (Miller, A.D. et al . Bio . Tech . (1989) 7:980-990).
  • neomycin phosphotransferase expression is controlled by the murine leukemia virus long terminal repeat
  • Wnt-5a-HA cDNA transcription is controlled by an internal CMV enhancer/promoter.
  • a full-length Wnt -5a cDNA was subcloned in antisense orientation (3 ' -5' ) .
  • HB2 human normal breast epithelial cell line
  • Various popula- tions of HB2 cells expressing the pLNCX empty vector (control) , the pLNCX-Wnt-5a-HA, or the pLNCX-Wnt-5a-HA in antisense orientation were isolated by growing the stable transfectants in the presence of 500 ⁇ g/ml geneticin. These cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 10 ⁇ g/ml bovine insulin, and 5 ⁇ g/ml hydrocortisone . All cell types were incubated at 37°C in a humidified atmosphere of 95% air and 5% carbon dioxide .
  • MCF-7 breast cancer cells were transfected with Wnt-5a cDNA and isolated stable transfectants expressing Wnt-5a-HA (Wnt-5a-expressing) and empty vector (control) under similar conditions as described for HB2 transfectants .
  • a Wnt-5a polyclonal antiserum was generated in rabbits immunised with a synthesised peptide corresponding to the C- terminal region of human and mouse Wnt-5a protein.
  • the serum was purified in two steps:
  • the anti-Wnt-5a antibody was used to screen several cell lines for expression of the Wnt-5a protein. The obtained results from cell lines for detection of the Wnt-5a protein were consistent with previous reports of Wnt-5a expression at the messenger RNA levels. Also isolated Wnt-5a antisense transfectants proved to express varying amounts of Wnt -5a protein, providing additional evidence of the specificity of the Wnt -5a antibody.
  • the experimental cells including Wnt-5a-overexpressing, antisense and control cells were detached from the tissue cul- ture plates using cell scrapers, and single-cell suspensions were prepared and washed twice in serum-free medium. Aliquots of single-cell suspensions (1 ml) containing 5 x 10 3 cells were plated on 24 well plates, coated with solutions of neutralised bovine dermal collagen type I (Vitrogen-100 , Colla- gen Corp.) in concentrations ranging from 1 to 100 ⁇ g/ml. The cells were incubated for 2 hours at 37°C. The wells were then gently washed three times with phosphate-buffered saline (PBS) to remove non-adherent cells.
  • PBS phosphate-buffered saline
  • Attached cells were fixed with 1% glutaraldehyde and stained with crystal violet (0.1% in H 2 0) , and the wells were subsequently washed with PBS three times. The relative number of attached cells in each well was evaluated by measuring absorbance at 540 nm in an ELISA Microplate Reader. The mean values (triplicate wells) for each concentration and population were calculated, and from those values, we subtracted non-specific cell adhesion measured on BSA-coated wells. As shown in Figure 2, the collagen-binding capacity of cells was significantly impaired in Wnt-5a antisense cells, as compared to Wnt-5a-overexpressing and control cells demonstrating a positive correlation between Wnt-5a protein expression and cell to matrix adhesion.
  • Single-cell suspensions of the experimental cell populations were prepared. Aliquots of the cell suspension were mixed with a neutralised collagen type I solution at a 1 : 10 ratio to give a final concentration of 1 x 10 5 cells/ml. The cell- collagen mixtures were then added to tissue culture plates (6 cm in diameter) and allowed to polymerise at 37°C for 1 hour.
  • the cells were either incubated in standard growth medium (Figure 3) or in standard growth medium supplemented with recombinant human HGF ( Figure 4) .
  • the cells were allowed to grow within the collagen gel for 7-8 days.
  • the appearance of produced morphogenetic structures was documented with a Nikon F 301 camera connected to a Nikon TMS inverted microscope.
  • the growth medium, with or without HGF, was replaced with fresh medium every other day.
  • the cells were either incubated in standard growth medium (Figure 3) or in standard growth medium supplemented with recombinant human HGF ( Figure 4) .
  • the cells were allowed to grow within the collagen gel for 7-8 days.
  • the appearance of produced morphogenetic structures was documented with a Nikon F 301 camera connected to a Nikon TMS inverted microscope.
  • the growth medium, with or without HGF, was replaced with fresh medium every other day.
  • the number of each type of structure was expressed as a percentage of the total number of structures present in the gel and the mean values were subsequently calculated.
  • the number of the generated cyst -shaped and branching structures by antisense cells was approximately 2 -fold compared to that produced by Wnt-5a-overexpressing or control cells.
  • Figure 4 shows a comparison of the cell branching in- tensity induced by HGF (an indicator of cell motility and invasion) in experimental cell populations.
  • the number of branches produced by antisense cells proved to be greater than 2-fold compared to that of control cells and 6-fold compared to that produced by Wnt-5a-overexpressing cells.
  • the rabbit polyclonal anti-Wnt-5a antibody was diluted 1:2000 and used under similar conditions as described above.
  • samples of the lysates were pre- cleared with protein-A Sepharose alone and subsequently incubated with 3 ⁇ g of anti-DDRl (Santa Cruz Biotechnology) or anti-phosphotyrosine antibody (4G10, Upstate Biotechnology, Inc.).
  • antigen-antibody complexes were collected using protein-A Sepharose.
  • the proteins were then separated on 8% SDS-polyacrylamide gels under reducing conditions and electrophoretically trans- ferred onto nitrocellulose membranes (Bio-Rad Laboratories) .
  • the membranes were incubated with anti-DDRl or 4G10 antibody.
  • Antigen-antibody association was detected using horseradish peroxidase conjugated secondary antibodies (DAKO, Denmark) and an enhanced chemiluminescence (ECL) detection system.
  • the DDR1 receptor was found to be expressed at a similar level in Wnt-5a-overexpressing, control, and antisense cells, but that suppression of the Wnt-5a protein led to significantly lower tyrosine phosphorylation of these receptors in the Wnt-5a antisense cells.
  • DDR1 protein was expressed in equal level in control, Wnt-5a-expressing, and parental MCF-7 cells. However, only the Wnt-5a-expressing cells showed a significant elevation of tyrosine phosphorylation of the DDR1 receptors.
  • Immuno-histochemical analysis of tumours were prepared on 3 - 5 ⁇ m sections cut on poly-L-lysine coated slides. Antigen retrieval was performed by incubating the dewaxed sections in a temperature-controlled microwave oven. The sections were allowed to cool to room temperature and were blocked with 1% BSA-PBS for non-specific antibody binding. Sections were then incubated with an anti-Wnt-5a antibody overnight at 4°C. A standard alkaline phosphatase technique was used for visualisation, and the expression was evaluated with a Leitz Diaplan microscope using 10 and 25x magnifying objectives.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un nouvel analogue peptidique de synthèse comprenant le domaine fonctionnel de la protéine Wnt-5a, une composition renfermant ledit analogue peptidique de synthèse, et un anticorps utilisé comme agent de diagnostic. La présente invention concerne également les utilisations de ce composé pour la fabrication d'un médicament ou d'un agent de diagnostic destiné au traitement ou au diagnostic de la métastase.
EP99960062A 1999-11-05 1999-11-05 Composes, anticorps et methodes destines au traitement, a la prevention ou au diagnostic de la metastase des tumeurs Withdrawn EP1226172A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SE1999/002009 WO2001032708A1 (fr) 1999-11-05 1999-11-05 Composes, anticorps et methodes destines au traitement, a la prevention ou au diagnostic de la metastase des tumeurs

Publications (1)

Publication Number Publication Date
EP1226172A1 true EP1226172A1 (fr) 2002-07-31

Family

ID=20415839

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99960062A Withdrawn EP1226172A1 (fr) 1999-11-05 1999-11-05 Composes, anticorps et methodes destines au traitement, a la prevention ou au diagnostic de la metastase des tumeurs

Country Status (3)

Country Link
EP (1) EP1226172A1 (fr)
AU (1) AU1700700A (fr)
WO (1) WO2001032708A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7682607B2 (en) 2001-05-01 2010-03-23 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US7713526B2 (en) 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
IL149404A0 (en) * 2002-04-29 2002-11-10 Yissum Res Dev Co METHODS AND COMPOSITIONS FOR MODULATING β-CATENIN PHOSPHORYLATION
ES2530263T3 (es) * 2005-05-30 2015-02-27 Wntresearch Ab Un ligando peptídico para alterar la migración de células cancerígenas
AU2009243233A1 (en) * 2008-04-30 2009-11-05 Wntresearch Ab Restoration of estrogen receptor-alpha activity
EP2726880B1 (fr) 2011-07-01 2019-04-17 Wntresearch AB Traitement du cancer de la prostate et procédé pour établir le pronostic de patients souffrant d'un cancer de la prostate
WO2016092378A1 (fr) 2014-12-10 2016-06-16 Angelo Luigi Vescovi Procédés et compositions de réduction de la croissance, de la migration et du caractère invasif des cellules souches du cancer du cerveau, et d'amélioration de la survie de patients atteints de tumeurs du cerveau

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5369498A (en) * 1996-11-27 1998-06-22 Penn State Research Foundation, The Compounds and methods for treating cancer
EP0885959A3 (fr) * 1997-05-23 2000-01-12 Smithkline Beecham Plc Protéine Wnt-5b humaine
US6485972B1 (en) * 1998-10-15 2002-11-26 President And Fellows Of Harvard College WNT signalling in reproductive organs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0132708A1 *

Also Published As

Publication number Publication date
AU1700700A (en) 2001-05-14
WO2001032708A1 (fr) 2001-05-10

Similar Documents

Publication Publication Date Title
Liu et al. Glycolysis links reciprocal activation of myeloid cells and endothelial cells in the retinal angiogenic niche
Hou et al. The critical role of CD133+ CD44+/high tumor cells in hematogenous metastasis of liver cancers
Penar et al. Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain
Kang et al. Activated STAT3 regulates hypoxia-induced angiogenesis and cell migration in human glioblastoma
Rubinstein et al. The distribution of myosin heavy chain isoforms among rat extraocular muscle fiber types
US9316654B2 (en) TAZ/WWTR1 for diagnosis and treatment of cancer
Sadanandam et al. High gene expression of semaphorin 5A in pancreatic cancer is associated with tumor growth, invasion and metastasis
McGary et al. A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo
Fournier et al. Interaction of E-cadherin and PTEN regulates morphogenesis and growth arrest in human mammary epithelial cells
Chiu et al. Glucose-regulated protein 78 regulates multiple malignant phenotypes in head and neck cancer and may serve as a molecular target of therapeutic intervention
Gallo et al. RANTES and IL-6 cooperate in inducing a more aggressive phenotype in breast cancer cells
US8383349B2 (en) Bone morphogenetic protein antagonist and uses thereof
Wong et al. Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer
Hao et al. JAM-C promotes lymphangiogenesis and nodal metastasis in non-small cell lung cancer
Zhang et al. Retracted: long noncoding RNA MT1JP inhibits proliferation, invasion, and migration while promoting apoptosis of glioma cells through the activation of PTEN/Akt signaling pathway
Xu et al. Hypoxia stimulates invasion and migration of human cervical cancer cell lines HeLa/SiHa through the Rab11 trafficking of integrin αvβ3/FAK/PI3K pathway-mediated Rac1 activation
Cui et al. B4GALT1 promotes immune escape by regulating the expression of PD-L1 at multiple levels in lung adenocarcinoma
Berns et al. Antiproliferative effects of suramin on androgen responsive tumour cells
CA3007877A1 (fr) Preparations combinees de modulateurs de pkm2 et de hmgb1
Liu et al. Calcineurin promotes proliferation, migration, and invasion of small cell lung cancer
Bello et al. IS20I, a specific αvβ3 integrin inhibitor, reduces glioma growth in vivo
Rashid et al. Identification of epitopes within integrin β4 for binding of auto-antibodies in ocular cicatricial and mucous membrane pemphigoid: preliminary report
He et al. Serglycin induces osteoclastogenesis and promotes tumor growth in giant cell tumor of bone
Dhawan et al. The lymphotoxin-β receptor is an upstream activator of NF-κB-mediated transcription in melanoma cells
Shi et al. Synthesis and Evaluation of 68Ga-NOTA-COG1410 Targeting to TREM2 of TAMs as a Specific PET probe for digestive tumor diagnosis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020412

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20030617

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031028